Evidence map›Paper›PMID 39313947›Full record

ArticleClinical and translational medicine2024

Rapid, portable Epstein‒Barr virus DNA detection using enzymatic recombinase amplification combined with the CRISPR-Cas12a system.

Jia Li, Hao Cheng, Xiaojun Wang, Ning Chen, Liujie Chen, Lili Duan, Fenghua Tan, Kai Li, Duanfang Liao, Zheng Hu

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Rapid and sensitive detection of bovineFrontiers in microbiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jia Li *The First Clinical College of Xiangnan University, the First Affiliated Hospital of Xiangnan University, the First People's Hospital of Chenzhou, Chenzhou, China.
Hao Cheng *Department of Nasopharyngeal Carcinoma, the First People's Hospital of Chenzhou, Hengyang Medical School, University of South China, Chenzhou, China.
Xiaojun Wang *Translational Medicine Institute, the First People's Hospital of Chenzhou, Hengyang Medical School, University of South China, Chenzhou, China.
Ning ChenThe First Clinical College of Xiangnan University, the First Affiliated Hospital of Xiangnan University, the First People's Hospital of Chenzhou, Chenzhou, China.
Liujie ChenThe First Clinical College of Xiangnan University, the First Affiliated Hospital of Xiangnan University, the First People's Hospital of Chenzhou, Chenzhou, China.
Lili DuanThe First Clinical College of Xiangnan University, the First Affiliated Hospital of Xiangnan University, the First People's Hospital of Chenzhou, Chenzhou, China.
Fenghua TanThe First Clinical College of Xiangnan University, the First Affiliated Hospital of Xiangnan University, the First People's Hospital of Chenzhou, Chenzhou, China.
Kai LiThe First Clinical College of Xiangnan University, the First Affiliated Hospital of Xiangnan University, the First People's Hospital of Chenzhou, Chenzhou, China.
Duanfang LiaoNational Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Hunan University of Chinese Medicine, Changsha, China.
Zheng HuThe First Clinical College of Xiangnan University, the First Affiliated Hospital of Xiangnan University, the First People's Hospital of Chenzhou, Chenzhou, China.ORCID 0000-0002-4078-5450

Funding

Innovative Team Project of the First People's Hospital of Chenzhou CX202103Key Project of the First People's Hospital of Chenzhou CZYY202203Key Science and Technology Program of Chenzhou ZDYF2020011Natural Science Foundation of Hunan Province 2021JJ30050Natural Science Foundation of Hunan Province 2023JJ50368Research Project of Xiangnan University 2019XJ74Science and Technology Program of Hunan Province 2021SK50305Science and Technology Program of Hunan Province 2021SK50313Scientific Research Project of Hunan Provincial Health Commission 202103100449Scientific Research Project of Hunan Provincial Health Commission 202203102912Scientific Research Project of Hunan Provincial Health Commission 202203103105Scientific Research Project of Hunan Provincial Health Commission W20243264Special funding fund for clinical research of Wu Jieping Foundation 320.6750.19094-25
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CRISPR-Cas SystemsDNA, ViralHerpesvirus 4, HumanHumansNucleic Acid Amplification TechniquesRecombinasesDNA, ViralRecombinases

Identifiers

PMID39313947
PMCPMC11420463

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.